Molecular profiling of tumors has been shown to improve risk stratification, and it may be useful for prostate cancer active surveillance.

In welcome good news, Telix says the first stage of its pivotal prostate cancer therapeutic trial has hit its desired safety ...

A new study led by researchers at The University of Texas MD Anderson Cancer Center found that prostate cancer patients with low testosterone levels may have a higher risk of cancer progressing to a ...

Thirty-six progressive mCRPC patients received TLX591-Tx across three cohorts (enzalutamide, abiraterone, or docetaxel sequence), and all completed two planned doses without emergent, unexpected ...

Prostate cancer is one of the most common cancers among men. Many cases grow slowly and may never become life-threatening. Because of this, doctors often recommend a management approach called “active ...

A PSA test in midlife could help to identify men at low risk of prostate cancer, supporting screening strategies and reducing overdiagnosis.

Candel Therapeutics Inc (NASDAQ:CADL) is advancing plans to bring its lead cancer immunotherapy toward potential ...

A novel immunotherapy combination is proving to be both safe and manageable for patients with prostate cancer, according to updated Phase 1 trial data presented at the 2026 ASCO Genitourinary Cancers ...

Baseline T may provide valuable information about prognosis.

A gene called FOXJ1 may drive resistance to taxane chemotherapy during treatment for advanced prostate cancer, according to a new study led by investigators at Weill Cornell Medicine and Beth Israel ...

Former President Joe Biden has been diagnosed with an aggressive form of prostate cancer that has spread to the bone. Last week, a “small nodule” was found on the 82-year-old Biden's prostate after ...